Oprl Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 24-10-2024
- Paid Up Capital ₹ 1.00 M
as on 24-10-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.20 M
as on 24-10-2024
- Revenue -47.95%
(FY 2023)
- Profit -53.21%
(FY 2023)
- Ebitda -43.09%
(FY 2023)
- Net Worth 10.44%
(FY 2023)
- Total Assets 10.45%
(FY 2023)
About Oprl Biosciences
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹3.20 M.
Saravanakumar and Raguraman Narayanasamy serve as directors at the Company.
- CIN/LLPIN
U29100TN2018PTC123374
- Company No.
123374
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jun 2018
- Date of AGM
05 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Oprl Biosciences Private Limited offer?
Oprl Biosciences Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Hematology Analyzers, Testing & Measuring Equipments, Test Kits, Inverters, UPS and Converters, Power Supply Systems, Rapid Test Kit, Laboratory & Lab Equipment, Laboratory Paper, Water Testing Kits.
Who are the key members and board of directors at Oprl Biosciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raguraman Narayanasamy  | Director | 25-Jun-2018 | Current |
| Saravanakumar | Director | 25-Jun-2018 | Current |
Financial Performance of Oprl Biosciences.
Oprl Biosciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 47.95% decrease. The company also saw a substantial fall in profitability, with a 53.21% decrease in profit. The company's net worth Soared by an impressive increase of 10.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oprl Biosciences?
In 2023, Oprl Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 28 Jun 2023 | ₹3.20 M | Open |
How Many Employees Work at Oprl Biosciences?
Unlock and access historical data on people associated with Oprl Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oprl Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oprl Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
